Market Tracker

05/18 5:15pm ET

Valeant Pharmaceuticals International Inc (NYSE:VRX)

22.14
Delayed Data
As of May 18
 +0.11 / +0.50%
Today’s Change
10.94
Today|||52-Week Range
24.43
+6.54%
Year-to-Date
The Bruce Fund Buys Buffett's Apple in 1st Quarter
May 18 / GuruFocus News - Paid Partner Content
Valeant (VRX) Rallies on Earnings Beat in Q1, Raises View
May 10 / Zacks.com - Paid Partner Content
Bruce & Co. Buys Apple Inc, International Business Machines Corp, Merck Inc, Sells Ca...
May 15 / GuruFocus News - Paid Partner Content
Aerie (AERI) Incurs Lower Loss in Q1, Launches Rhopressa
May 09 / Zacks.com - Paid Partner Content
May 15 Forum Update: 'Buffett CNBC' Edition
May 15 / GuruFocus News - Paid Partner Content
Valeant Pharmaceuticals (VRX) Catches Eye: Stock Jumps 8.9%
May 09 / Zacks.com - Paid Partner Content
What Does Francis Chou See in Valeant?
May 15 / GuruFocus News - Paid Partner Content
Drug/Biotech Q1 Earnings Lineup on May 8: JAZZ, ARNA & More
May 07 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close22.03
Today’s open22.06
Day’s range21.97 - 22.24
Volume5,488,345
Average volume (3 months)10,715,196
Market cap$7.3B
Data as of 4:01pm ET, 05/18/2018

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)-19.38%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)-9.82%
P/E ratioNM
Price/Sales0.84
Price/Book1.24

Competitors

 Today’s
change
Today’s
% change
GLPGGalapagos NV+0.91+0.94%
ACADACADIA Pharmaceutica...-0.13-0.72%
TAROTaro Pharmaceutical ...-2.55-2.21%
----
Data as of 4:02pm ET, 05/18/2018

Financials

Next reporting dateAugust 7, 2018
EPS forecast (this quarter)$0.75
Annual revenue (last year)$8.7B
Annual profit (last year)$2.4B
Net profit margin27.56%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Joseph C. Papa
Chief Financial Officer &
Executive Vice President
Paul S. Herendeen
Corporate headquarters
Laval, Quă©bec

Forecasts